Menu
1. HIGHLIGHTS OF THE 2019 CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC)
2. Conflicts of interest
3. KEY FIGURES ESC CONGRESS
4. LATE BREAKING TRIALS
5. ESC CONGRESS PROGRAMME COMMITTEE 2019
6. LATE BREAKING TRIALS
7. HEART FAILURE
8. PARAGON-HF study design
9. PARAGON-HF primary results Recurrent event analysis of total HF hospitalisations and CV death*
10. HF hospitalisations and CV death
11. Significant Heterogeneity in Multivariate Analysis by Ejection Fraction and Sex
12. Dapagliflozin in patients with HFrEF (DAPA-HF): Rationale
13. Dapagliflozin in patients with HFrEF (DAPA-HF)
14. Primary composite outcome
15. No diabetes/diabetes subgroup: Primary endpoint
16. DAPA-HF Components of primary outcome
17. Acute Coronary syndromes
18. NZOTACS
19. ISAR-REACT 5
20. ISAR-REACT 5
21. ISAR-REACT 5
22. Coronary revascularization
23. COMPLETE Trial design
24. COMPLETE: Main results
25. COMPLETE: Timing of non-culprit lesion PCI: During or after initial hospitalisation
26. BIOSTEMI: Results
27. SYNTAXES 10 yr all cause death
28. SYNTAXES: Diabetes
29. Prevention
30. THEMIS
31. THEMIS-PCI – Prespecified subgroup analysis
32. Study Deisgn
33. Themis
34. Themis-PCI - Prespecified subgroup analysis
35. CONCLUSIONS
36. CONCLUSIONS
Highlights of the 2019 Congress of ESC, Pr Marco Roffi
Resources
Here are some useful links and documents:
Title
Title
Title
FINISH
SUBMIT
NEXT
PREV
Submit All